Screener
UroGen Pharma URGN Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Non-current liabilities: | ||
| Prepaid forward obligation | 125,135 | 127,276 |
| Long-term debt | 188,734 | 122,210 |
| Finance long-term lease liabilities | 2,939 | 3,475 |
| Operating long-term lease liabilities | 2,360 | 2,647 |
| Uncertain tax positions liability | 3,903 | 3,903 |
| Total liabilities | 384,986 | 305,929 |
| Commitments and contingencies (Note 19) |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's finance lease liabilities?
- UroGen Pharma (URGN) reported finance lease liabilities of $2.94M in Q2 2026.
- How has UroGen Pharma's finance lease liabilities changed year-over-year?
- UroGen Pharma's finance lease liabilities increased by 2.7% year-over-year, from $2.86M to $2.94M.
- What is the long-term trend for UroGen Pharma's finance lease liabilities?
- Over 2 years (2023 to 2025), UroGen Pharma's finance lease liabilities has grown at a 102.9% compound annual growth rate (CAGR), from $844K to $3.48M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about UroGen Pharma's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude